Journal article icon

Journal article

Integrating next-generation dendritic Cell vaccines into the current cancer immunotherapy landscape.

Abstract:

Cancer immunotherapy is experiencing a renaissance spearheaded by immune checkpoint inhibitors (ICIs). This has spurred interest in 'upgrading' existing immunotherapies that previously experienced only sporadic success, such as dendritic cells (DCs) vaccines. In this review, we discuss the major molecular, immunological, and clinical determinants of existing first- and second-generation DC vaccines. We also outline the future trends for next-generation DC vaccines and describe their major hal...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1016/j.it.2017.05.006

Authors


More by this author
Department:
Oxford, MSD, NDM, Oxford Ludwig Institute
Role:
Author
Flemish National Fund for Scientific Research More from this funder
University of Leuven More from this funder
Belgian State More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Trends in Immunology Journal website
Volume:
38
Issue:
8
Pages:
577-593
Publication date:
2017-06-10
DOI:
EISSN:
1471-4981
ISSN:
1471-4906
Pubs id:
pubs:701188
URN:
uri:58ed6c1b-0344-41c1-b64a-78b491482843
UUID:
uuid:58ed6c1b-0344-41c1-b64a-78b491482843
Local pid:
pubs:701188
Language:
English
Keywords:

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP